Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
High maternal levels of liver damage markers in the blood can predict poor fetal outcomes in twin pregnancies affected by intrahepatic cholestasis of pregnancy…
People with Alagille syndrome display different disease characteristics depending on whether the disease-causing mutation is located in the JAG1 gene or the NOTCH2 gene,…
An unreported mutation in the JAG1 gene was identified as the likely cause of Alagille syndrome in a 28-year-old woman, a case report from…
Hoth Therapeutics will support a U.S. Department of Veterans Affairs (VA) study testing treatment with glial cell-derived neurotrophic factor (GDNF) against semaglutide in a…
Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does so at a faster rate,…
The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).
Note: This story was updated Aug. 8, 2025, to correct that infectious mononucleosis was linked to a 4.6 times higher risk of future PSC, not  a…
A combination of two mutations in the MYO5B gene, including one that has not been previously reported, was the likely cause of a mild form…
